Interpace to Present at the American College of Gastroenterology Conference
October 24 2019 - 6:55AM
Interpace (IDXG) announced today that it will be presenting new
data on the performance of its molecular thyroid and GI products at
an industry known scientific international meeting. The American
College of Gastroenterology annual meeting is held on October 27-30
in San Antonio, Texas and is one of the largest gatherings of
gastroenterologists and endoscopists. These are two key targets for
Interpace’s PancraGEN® test for early detection of cancer in
indeterminate pancreatic cysts, solid lesions, and biliary
structures. The PancraGEN publication entitled “Serial molecular
testing of pancreatic cyst fluid over time: progression and
regression” highlights the Company’s unique clinical and molecular
database of patient results, examining 2,167 patients with
pancreatic cysts that underwent multiple PancraGEN tests over time.
The results support the high negative predictive value of
PancraGEN, showing that the majority of cases (92%) initially found
to have low risk PancraGEN results remained low risk at follow-up.
The small portion of patients that did progress only progressed to
moderate risk levels, where risk most often regressed to low risk
over time.
In addition to the poster, Interpace will host
its second annual Fellows program. The keynote speakers will be Dr.
Tamas Gonda, Columbia University, and Dr. James Farrell, Yale
University. Dr.’s Gonda and Farrell are going to be discussing
their peer-reviewed published work on the utility of DNA analysis
in managing patients with pancreatic cysts, describing molecular
results of patients who have undergone PancraGEN® testing and how
those results can be used to impact patient management
decisions.
About Interpace
Interpace is a leader in enabling personalized
medicine, offering specialized services along the therapeutic value
chain from early diagnosis and prognostic planning to targeted
therapeutic applications.
Interpace’s Diagnostic Business is a fully
integrated commercial and bioinformatics business unit that
provides clinically useful molecular diagnostic tests,
bioinformatics and pathology services for evaluating risk of cancer
by leveraging the latest technology in personalized medicine for
improved patient diagnosis and management. Interpace has four
commercialized molecular tests and one test in a clinical
evaluation process (CEP): PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT®
for the diagnosis of thyroid cancer from thyroid nodules utilizing
a next generation sequencing assay; ThyraMIR® for the diagnosis of
thyroid cancer from thyroid nodules utilizing a proprietary gene
expression assay; and RespriDX® that differentiates lung cancer of
primary vs. metastatic origin. In addition, BarreGEN® for Barrett’s
Esophagus, is currently in a clinical evaluation program whereby we
gather information from physicians using BarreGEN® to assist us in
positioning the product for full launch, partnering and potentially
supporting reimbursement with payers.
Interpace’s Biopharma Business provides
pharmacogenomics testing, genotyping, biorepository and other
customized services to the pharmaceutical and biotech industries.
The Biopharma Business also advances personalized medicine by
partnering with pharmaceutical, academic, and technology leaders to
effectively integrate pharmacogenomics into their drug development
and clinical trial programs with the goals of delivering safer,
more effective drugs to market more quickly, and improving patient
care.
For more information, please visit Interpace’s
website at www.interpacediagnostics.com.
Forward-looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance. The Company
has attempted to identify forward looking statements by terminology
including "believes," "estimates," "anticipates," "expects,"
"plans," "projects," "intends," "potential," "may," "could,"
"might," "will," "should," "approximately" or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are based on current
expectations, assumptions and uncertainties involving judgments
about, among other things, future economic, competitive and market
conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are
beyond the Company's control. These statements also involve known
and unknown risks, uncertainties and other factors that may cause
the Company's actual results to be materially different from those
expressed or implied by any forward-looking statement. Known and
unknown risks, uncertainties and other factors include, but are not
limited to the fact that there is no assurance the acquisition of
the BioPharma business of Cancer Genetics, Inc. will be
successfully integrated with the Company, or that the potential
benefits of the acquisition, including future revenues, will be
successfully realized. Additionally, all forward-looking statements
are subject to the “Risk Factors” detailed from time to time in the
Company's most recent Annual Report on Form 10-K, Current Reports
on Form 8-K and Quarterly Reports on Form 10-Q. Because of these
and other risks, uncertainties and assumptions, undue reliance
should not be placed on these forward-looking statements. In
addition, these statements speak only as of the date of this press
release and, except as may be required by law, the Company
undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
CONTACTS:Investor Relations - Edison GroupJoseph Green(646)
653-7030jgreen@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024